Cargando…

Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke

Background: Hemorrhagic transformation, neurotoxicity, short treatment time windows, and other defects are considered as the major limitations for the thrombolytic therapy. This study is devoted to figure out whether Danhong injection (DHI) combined with tissue-plasminogen activator (t-PA) could ext...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Min, Zhou, Jing, Jin, Weifeng, Li, Xiaohong, Zhang, Yuyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897498/
https://www.ncbi.nlm.nih.gov/pubmed/29681849
http://dx.doi.org/10.3389/fphar.2018.00308
_version_ 1783313974041772032
author Li, Min
Zhou, Jing
Jin, Weifeng
Li, Xiaohong
Zhang, Yuyan
author_facet Li, Min
Zhou, Jing
Jin, Weifeng
Li, Xiaohong
Zhang, Yuyan
author_sort Li, Min
collection PubMed
description Background: Hemorrhagic transformation, neurotoxicity, short treatment time windows, and other defects are considered as the major limitations for the thrombolytic therapy. This study is devoted to figure out whether Danhong injection (DHI) combined with tissue-plasminogen activator (t-PA) could extend the treatment time windows and ameliorate brain injury, hemorrhagic complication and BBB disruption after focal embolic stroke. Methods: In vitro, the combined concentrations of DHI and t-PA were added to wells reacted with plasminogen and D-Val-Leu-Lys-AMC. The optimum ratio of the combination of DHI plus t-PA was explored by detecting relative fluorescent. In vivo experiments, we firstly investigated the optimal dose of t-PA and Danhong injection for focal embolic stroke. The neurological deficit score, infarct volume and brain edema were assessed. Secondly, we proved that the combination group extended the thrombolytic window for treatment of focal embolic stroke. The neurological deficit score, infarct volume, brain edema and hemorrhagic complication were assessed, while levels of BAX, Bcl-2 and caspase-3 in brain tissue were analyzed by real-time polymerase chain reaction. Finally, to ask whether combination therapy with DHI plus t-PA protected the blood–brain barrier in a rat model of focal embolic stroke, neurological deficit score, ELISA, RT-PCR, western blot and fluorescence were used to detect the indicators of blood–brain barrier, such as tight junction protein, blood–brain barrier permeability and related gene expression. Results: In vitro, plasmin activity assays showed that the combination of t-PA with DHI at about 1:1.6 w/v ratio increased by almost 1.4-fold the plasmin-generating capability of t-PA. In vivo experiments, the results showed that the combination of Danhong injection (4 mL/kg) and t-PA (2.5 mg/kg) could extend the t-PA treatment time windows to 4.5 h. And the combination t-PA (2.5 mg/kg) with DHI (4 mL/kg) ameliorated neurological score, cerebral infarction, brain edema, brain hemorrhage, and BBB disruption. Conclusion: Combination therapy with Danhong injection (4 mL/kg) plus t-PA (2.5 mg/kg) could extend the t-PA treatment time windows to 4.5 h, ameliorate BBB disruption, reduce infarction, brain swelling and hemorrhage after ischemic stroke.
format Online
Article
Text
id pubmed-5897498
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58974982018-04-20 Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke Li, Min Zhou, Jing Jin, Weifeng Li, Xiaohong Zhang, Yuyan Front Pharmacol Pharmacology Background: Hemorrhagic transformation, neurotoxicity, short treatment time windows, and other defects are considered as the major limitations for the thrombolytic therapy. This study is devoted to figure out whether Danhong injection (DHI) combined with tissue-plasminogen activator (t-PA) could extend the treatment time windows and ameliorate brain injury, hemorrhagic complication and BBB disruption after focal embolic stroke. Methods: In vitro, the combined concentrations of DHI and t-PA were added to wells reacted with plasminogen and D-Val-Leu-Lys-AMC. The optimum ratio of the combination of DHI plus t-PA was explored by detecting relative fluorescent. In vivo experiments, we firstly investigated the optimal dose of t-PA and Danhong injection for focal embolic stroke. The neurological deficit score, infarct volume and brain edema were assessed. Secondly, we proved that the combination group extended the thrombolytic window for treatment of focal embolic stroke. The neurological deficit score, infarct volume, brain edema and hemorrhagic complication were assessed, while levels of BAX, Bcl-2 and caspase-3 in brain tissue were analyzed by real-time polymerase chain reaction. Finally, to ask whether combination therapy with DHI plus t-PA protected the blood–brain barrier in a rat model of focal embolic stroke, neurological deficit score, ELISA, RT-PCR, western blot and fluorescence were used to detect the indicators of blood–brain barrier, such as tight junction protein, blood–brain barrier permeability and related gene expression. Results: In vitro, plasmin activity assays showed that the combination of t-PA with DHI at about 1:1.6 w/v ratio increased by almost 1.4-fold the plasmin-generating capability of t-PA. In vivo experiments, the results showed that the combination of Danhong injection (4 mL/kg) and t-PA (2.5 mg/kg) could extend the t-PA treatment time windows to 4.5 h. And the combination t-PA (2.5 mg/kg) with DHI (4 mL/kg) ameliorated neurological score, cerebral infarction, brain edema, brain hemorrhage, and BBB disruption. Conclusion: Combination therapy with Danhong injection (4 mL/kg) plus t-PA (2.5 mg/kg) could extend the t-PA treatment time windows to 4.5 h, ameliorate BBB disruption, reduce infarction, brain swelling and hemorrhage after ischemic stroke. Frontiers Media S.A. 2018-04-06 /pmc/articles/PMC5897498/ /pubmed/29681849 http://dx.doi.org/10.3389/fphar.2018.00308 Text en Copyright © 2018 Li, Zhou, Jin, Li and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Min
Zhou, Jing
Jin, Weifeng
Li, Xiaohong
Zhang, Yuyan
Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke
title Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke
title_full Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke
title_fullStr Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke
title_full_unstemmed Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke
title_short Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke
title_sort danhong injection combined with t-pa improves thrombolytic therapy in focal embolic stroke
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897498/
https://www.ncbi.nlm.nih.gov/pubmed/29681849
http://dx.doi.org/10.3389/fphar.2018.00308
work_keys_str_mv AT limin danhonginjectioncombinedwithtpaimprovesthrombolytictherapyinfocalembolicstroke
AT zhoujing danhonginjectioncombinedwithtpaimprovesthrombolytictherapyinfocalembolicstroke
AT jinweifeng danhonginjectioncombinedwithtpaimprovesthrombolytictherapyinfocalembolicstroke
AT lixiaohong danhonginjectioncombinedwithtpaimprovesthrombolytictherapyinfocalembolicstroke
AT zhangyuyan danhonginjectioncombinedwithtpaimprovesthrombolytictherapyinfocalembolicstroke